Description
Release form
Tablets.
Packing
28 pcs.
Pharmacological action
MIKARDIS – antihypertensive agent, angiotensin II receptor antagonist (type AT1). It has a very high affinity for this receptor subtype. Selectively and continuously binding to receptors, telmisartan displaces angiotensin II from its association with AT1 receptors. No affinity for other subtypes of AT receptors. The functional significance of other subtypes of receptors and the effect of increased (as a result of the appointment of telmisartan) levels of angiotensin II on them is not known. Telmisartan reduces plasma aldosterone levels, does not inhibit plasma renin, does not block ion channels, does not inhibit ACE (kinase II), which also destroys bradykinin. Therefore, the manifestation of side effects associated with bradykinin is not observed.
Contraindications
Obstruction of the biliary tract, severe hepatic and renal impairment, pregnancy, lactation (breastfeeding), hypersensitivity to telmisartan.
Specific guidance
Impact on the ability to drive a car and machinery
No specific studies have been conducted on the effect of the drug on a ability to drive a car and machinery. However, when driving a car and machinery, one should remember the possibility of developing dizziness and drowsiness with the use of drugs used to treat arterial hypertension.
Composition
1 tab. contains telmisartan 80 mg excipients: polyvidone meglumine sodium hydroxide sorbitol magnesium stearate.
Dosage and administration of
For adults, the daily dose is 20-40 mg (1 time / day). In some patients, a hypotensive effect can be achieved at a dose of 20 mg / day. If necessary, the dose can be increased to 80 mg / day.
Patients with impaired renal function, as well as elderly patients, do not need dose adjustment.
For patients with impaired liver function, the daily dose is 40 mg.
Side effects
From the nervous system: headache, dizziness, fatigue, insomnia, anxiety, depression, cramps.
From the respiratory system: upper respiratory tract infections (including pharyngitis, sinusitis, bronchitis), cough.
From the cardiovascular system: marked decrease in blood pressure, bradycardia, tachycardia, chest pain.
From the digestive system: nausea, dyspepsia, diarrhea, abdominal pain, increased activity of “liver” transaminases.
From the musculoskeletal system: myalgia, arthralgia, lower back pain, symptoms similar to tendonitis.
From the urinary system: peripheral edema, urinary tract infection, hypercreatininemia.
Allergic reactions: skin rash, etc.
Laboratory indicators: rarely – hyperkalemia, anemia or hyperuricemia.
Other: flu-like syndrome, rarely – erythema, pruritus, syncope, dyspnea, eosinophilia, thrombocytopenia, angioedema, hives.
Drug interaction
When used with antihypertensive drugs, an increase in antihypertensive effect is possible.
With simultaneous use with potassium-sparing diuretics, heparin, dietary supplements, salt substitutes containing potassium, the development of hyperkalemia is possible.
With simultaneous use with lithium preparations, an increase in the concentration of lithium in blood plasma is possible.
With simultaneous use, an increase in the concentration of digoxin in blood plasma is possible.
Overdose
No cases of overdose in humans have been identified.
Symptoms: marked decrease in blood pressure.
Treatment: in the event of a marked decrease in blood pressure, symptomatic therapy should be given. Hemodialysis is not effective.
Storage conditions
In a dark place at a temperature not exceeding 20 ° C.
Expiration
4 years.
active substance
Telmisartan
Terms leave through pharmacies
In retseptu
lekarstvennaja form
tablets
Beringer Ingelyhaym, Germany
